 |
| Dear Newsmax Reader: Please find below a special message from our sponsoring advertiser, PositiveID Corporation. They have important information to share with you. Thank you. Newsmax.com |
 PositiveID's innovative and advanced healthcare and medical solutions, developed from its expanding intellectual property portfolio, are designed to address unmet needs in the market.
From non-invasive blood glucose monitoring through the creation of novel sensing devices, to rapid and precise biological detection at the point-of-care, PositiveID provides tools for a better quality of life.
Investors are taking notice with the release of today's press release.
Put PSID on your radar Screens! |  |
 | Breaking News For PositiveID Corporation | PositiveID Corporation Receives an Additional Key Patent for Fieldable Biological Detection Portable technology can be used to detect pathogens in both field and clinical environments for rapid diagnosis and treatment
DELRAY BEACH, FL - PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID - News), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, recentley announced that it has been awarded an additional important international patent "Apparatus and Method of Extracting and Optically Analyzing an Analyte from a Fluid-based Sample," (WO2008/005166) by the World Intellectual Property Organization. The technology represented by this new patent, awarded to the Company's MicroFluidic Systems ("MFS") subsidiary, works in conjunction with the patented technology which the Company announced in mid-July. The technologies provide key steps in accurate biological sample preparation and detection with limited resources, and in the field or clinical environment.
The handheld instrument is small enough, about the size of a syringe, that it could be carried easily by a medical provider and used with a minimal amount of training and time. This technology can allow rapid detection within minutes of a sampling allowing appropriate treatment for infected individuals immediately. The system works entirely on batteries.
Dr. M. Allen Northrup, CEO of MFS, said, "The two new patents announced over the past couple of weeks are noteworthy for their ability to run biological sample analysis in a small, portable and cost-efficient format and provide rapid, accurate detection. We believe this technology has significant value for multiple applications of critical importance to prevent disease outbreaks and save lives."
The unique component of the technology is a very low power optical analysis system directly coupled to the collection system to perform optical analysis on multiple collected analytes. The purification device includes a plurality of capture surfaces coated with specific capture chemistries. The specific capture can be for a nucleic acid, protein or other target analyte, and multiple options for optical detection exist. PositiveID acquired MFS in May 2011. MFS specializes in the production of automated instruments for a wide range of applications in the detection and processing of biological samples. MFS' strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
| Company Profile - PositiveID Corporation |
 | PositiveID Corporation (NASDAQ: PSID) develops unique medical devices and biological detection systems focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID Corporation was formed on November 10, 2009 through the merger of VeriChip Corporation and Steel Vault Corporation.
In May 2011, PositiveID acquired California-based Microfluidic Systems, founded in 2001, which specializes in the development and production of automated instruments for detecting and processing of biological samples. MFS' core technology is used for airborne pathogen detection, rapid clinical diagnostics and sample preparation applications.
MFS' microfluidic technology alleviates all existing problems by replacing robotics with integrated microfluidics, reducing cost and increasing reliability. Our microfluidic technology also automates and increases the effectiveness of key sample processing steps used today on the laboratory bench-top, into a closed automated system. The embedded devices perform cell lysis (including difficult spores) in less than 1 minute at low power, nucleic acid purification along with inhibitor removal and pre-concentration of the nucleic acids up to factors of 1000X within minutes. These processes all occur autonomously within a fully contained disposable microfluidic cartridge.
PositiveID operates in two main divisions: HealthID and SecurityID. The HealthID segment develops unique medical devices, focused primarily on diabetes management, and rapid medical testing applications. Its SecurityID segment develops airborne bio-threat detection systems.
An integral part of the history of PositiveID is its radio-frequency identification (RFID) implantable microchip for patient identification, the VeriChip. The company's RFID microchip traces back to the events of September 11, 2001, when New York firemen wrote their badge ID numbers on their chests in case they were found injured or unconscious. It was evident there was a serious need for personal information in emergency situations and the product, modeled after a similar microchip used in pets, evolved from there. The company received FDA clearance for the microchip in October 2004. | | Recent News from PositiveID Corporation |
| PUT PSID ON YOUR WATCHLIST TODAY! | | | | | FORWARD LOOKING STATEMENTS These news releases include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements that reflect PositiveID Corporation's current expectations about its future results, performance, prospects and opportunities. PositiveID Corporation has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "hope," or similar expressions. These forward-looking statements are based on information currently available to PositiveID Corporation and are subject to a number of risks, uncertainties and other factors that could cause PositiveID Corporation's actual results, performance, prospects or opportunities in the remainder of 2011 and beyond to differ materially from those expressed in, or implied by, these forward-looking statements. These risks are referenced in PositiveID Corporation's current 10K or as may be described from time to time in PositiveID Corporation's subsequent SEC filings; and such factors as incorporated by reference. DISCLAIMER: Hanover Financial Services, a professional business development and marketing consulting firm, has paid a fee of nine thousand one hundred dollars to Newsmax Media. Inc. from PostiveID Corporation for marketing and communication consulting services associated with the distribution of this publication This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Therefore, INVESTORS SHOULD NOT BASE ANY INVESTMENT DECISION ON ANY MATERIALS FOUND IN THIS PUBLICATION. All direct and third party compensation received has been disclosed in accordance with section 17(b) of the Securities Act of 1933.
| | |
This e-mail is never sent unsolicited. You have received this Newsmax e-mail because you subscribed to it or someone forwarded it to you. To opt out, see the links below.
| | | For information on advertising, please contact Newsmax Advertising Sales via e-mail. | | | | If this e-mail has been forwarded to you and you would like to sign up, please click here. | Remove your e-mail address from our list or modify your profile. We respect your right to privacy. View our policy.
This e-mail was sent by:
Newsmax.com
4152 West Blue Heron Blvd., Ste. 1114
Riviera Beach, FL 33404 USA
1232218
 | |
No comments:
Post a Comment